Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
INVAGESIC vs PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination